59184-90-6

Usage

InChI:InChI=1/C9H17NO2/c1-2-12-9(11)7-8-3-5-10-6-4-8/h8,10H,2-7H2,1H3

Upstream product

• 102879-50-5 ethyl 4-pyridylacetate hydrochloride 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 54401-85-3 pyridin-4-yl-acetic acid ethyl ester 
• 82244-11-9 ethyl-1-carbobenzoxy-Δ^4,α-piperidine-4-acetate 
• 40110-55-2 ethyl 2-(1-benzylpiperidine-4-ylidene)acetate 
• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 
• 623-48-3 ethyl iodoacetae 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 95798-23-5 1-(benzyloxycarbonyl)-4-hydroxypiperidine 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 186581-53-3 diazomethane 

Downstream Products

• 54108-67-7 N-benzoyl-4-(carbethoxymethyl)piperidine 
• 98430-74-1 [4]piperidyl-acetic acid hydrazide 
• 51052-78-9 4-piperidinylacetic acid 
• 71879-59-9 ethyl (1-benzylpiperidin-4-yl)acetate 
• 200490-81-9 [1-(3-tert-Butoxycarbonylamino-2,2-dimethyl-pentanoyl)-piperidin-4-yl]-acetic acid ethyl ester 
• 374776-37-1 4-(2-ethoxy-5-(4-(ethoxycarbonylmethyl)piperidinylsulfonyl)benzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide 
• 374776-38-2 4-(5-(4-(ethoxycarbonylmethyl)piperidinylsulfonyl)-2-n-propoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide 
• 888736-24-1 [1-(3-iodo-benzoyl)-piperidin-4-yl]-acetic acid ethyl ester 
• 902770-73-4 ethyl [1-[(4R)-benzyloxy-1-(tert-butoxycarbonyl)-(2S)-pyrrolidinylcarbonyl]-4-piperidinyl]acetate 
• 886447-79-6 ethyl [1-[1-(tert-butoxycarbonyl)-(4R)-methoxy-(2S)-pyrrolidinylcarbony]-4-piperidinyl]acetate 
• 923945-25-9 [1-(4-acetyl-phenyl)-piperidin-4-yl]-acetic acid ethyl ester 
• 903499-14-9 ethyl [1-[(4R)-benzyloxy-(2S)-pyrrolidinylcarbonyl]-4-piperidinyl]acetate 
• 886447-76-3 [1-((2S,4R)-4-Benzyloxy-1-{2-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-acetyl}-pyrrolidine-2-carbonyl)-piperidin-4-yl]-acetic acid 
• 903499-17-2 ethyl [1-[(4R)-benzyloxy-1-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylcarbonyl]-4-piperidinyl]acetate 

Relevant academic research and scientific papers

Chemoselective catalytic hydrogenation of alkenes by Lindlar catalyst

Commercially available Lindlar catalyst (10% by weight) in methanol, selectively hydrogenates various alkenes in the presence of benzyl ether and benzyl amine functionalities.

Therapeutic Uses

This invention relates to novel therapeutic uses for compounds which are inverse agonists of the H3 receptor. In particular this invention relates to therapeutic use of these compounds in the treatment of Multiple Sclerosis.

HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.

HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.

THERAPEUTIC USES

This invention relates to novel therapeutic uses for compounds which are inverse agonists of the H3 receptor. In particular this invention relates to therapeutic use of these compounds in the treatment of Multiple Sclerosis.

Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13

The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would therefore be a novel disease modifying therapy for the treatment of arthritis. Our efforts have resulted in the discovery of a series of carboxylic acid inhibitors of MMP-13 that do not significantly inhibit the related MMP-1 (collagenase-1) or tumor necrosis factor-α (TNF-α) converting enzyme (TACE). It has previously been suggested (but not proven) that inhibition of the latter two enzymes could lead to side effects. A promising carboxylic acid lead 9 was identified and a convergent synthesis developed. This paper describes the optimization of 9 and the identification of a compound 24f for further development. Compound 24f is a subnanomolar inhibitor of MMP-13 (IC50 value 0.5 nM and Ki of 0.19 nM) having no activity against MMP-1 or TACE (IC50 of >10000 nM). Furthermore, in a rat model of MMP-13-induced cartilage degradation, 24f significantly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition, p 0.05) and at 10 mg/kg (40% inhibition, p 0.05).

Microwave-assisted hydrogenation of pyridines

Using a commercially available device for controlled introduction of hydrogen in a vial for reactions under microwave dielectric heating, we developed a protocol for the transformation of substituted pyridines into the corresponding piperidines. Complete reduction occurred in 40 minutes, or even less, on substrates that require 24-48 hours to be reduced under standard conditions. Moreover, the reduction proved to be as stereoselective as the corresponding reaction carried out at room temperature. Georg Thieme Verlag Stuttgart.

COMPOSITIONS AND METHODS INCLUDING CELL DEATH INDUCERS AND PROCASPASE ACTIVATION

Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.

3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)

A novel series of cyclic potent, selective, small molecule, thiol-based inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) and the crystal structures of TAFIa inhibitors bound to porcine pancreatic carboxypeptidase B are described. Three series of cyclic arginine and lysine mimetic inhibitors vary significantly in their selectivity against other human basic carboxypeptidases, carboxypeptidase N and carboxypeptidase B. (-)2a displays TAFIa IC50 = 3 nM and 600-fold selectivity against CPN. Inhibition of TAFIa with (rac)2a resulted in dose dependent acceleration of human plasma clot lysis in vitro and was efficacious as an adjunct to tPA in an in vivo rabbit jugular vein thrombolysis model.

NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR, wherein R is O-, -CH3 or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR or CR; or each of a, b, c and d is independently selected from CR or CR; each R and each R is independently selected from H, halo, -CR3, -OR, -COR, -SR, -S(O)tR (wherein t is 0, 1 or 2), -SCN, -N(R)2, -NRR, -NO2, -OC(O)R, -CO2R, -OCO2R, -CN, -NHC(O)R, -NHSO2R, -CONHR, -CONHCH2CH2OH, -NRCOOR, -SRC(O)OR, -SRN(R); n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO2-; or -CRR-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR, -SR, -CRR, -NRR, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.